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CLARIFICATION OF
STATEMENTS MADE
REGARDING INVESTIGATION
INTO AMPLATZER DEVICE
COMPLICATION INCIDENCE
AND COMPARISON WITH THE
SOCIETY OF THORACIC
SURGERY DATABASE
To the Editor:
As the corresponding first author and
presenter of the article regarding the
Amplatzer device (AGA Medical
Corporation, Plymouth, Minn) compli-
cations and comparison with the Soci-
ety of Thoracic Surgery database,1
I must clarify some statements made re-
garding the work of previous authors on
the complications of the Amplatzer de-
vice.2 In formulating a calculation that
was used to estimate complication fre-
quency, we based our mathematics on
estimates that were previously used by
Amin and colleagues.2 Our point in not-
ing that there was financial disclosure in
the previous work was not to suggest
that the data were not accurate. In fact,
we were counting on the accuracy of
these data because we also used the
data for our calculation. Rather than
questioning the work of these authors,
we were in fact relying on the integrity
of their estimates to make our own cal-
culations. The authors most closely as-
sociated with this device serve as the
best possible source of such informa-
tion, and highlighting this relationship
was only intended to add validity to
our own calculation.
There was absolutely no intended
implication of foul play or acting in
conflict of interest in the case of these
authors and indeed no such accusation
was directly made. That some compli-
cations go unreported to the MAUDE
database is most probably true but
this has nothing to do with the work
of Amin and colleagues,2 and these
must be kept seperate in the readers’
minds to understand the spirit of this
work. The previous publications on
the complications with Amplatzer de-
vices were as accurate as any, and
our addition to the literature presents
the most up to date. That the frequency
LETTERS TO THE EDITORTHE LEFT VENTRICLE: TO
RECONSTRUCT OR NOT—
LESSONS FROM THE STICH
TRIAL
To the Editor:
Recently at the 89th Annual Meeting
of The American Association for Tho-
racic Surgery in Boston, May 9–13,
2009, there was a very clarifying
debate on the STICH trial1 (Surgical
Treatment for Ischemic Heart Failure)
between Dr Robert H. Jones (pro) and
Dr Gerald D. Buckberg (con), moder-
ated by Dr Andrew S. Wechsler, which
sparked the following thoughts.
Clearly, surgeons involved in the
STICH trial had a difficult job: they
were instructed to include patients in
the trial if they honestly believed
they could undergo coronary artery
bypass grafting (CABG) either alone
or in combination with surgical ven-
tricular reconstruction (SVR) with
safety. It would seem likely that, ethi-
cally, patients with either global
hypokinesis (no clear-cut aneurysm)
or those with large aneurysms would
be hard to include in this trial. Also, re-
sults of the two patient groups (CABG
alone vs CABGþSVR) are uncannily
similar: identical improvements in
congestive heart failure and angina
class for both groups (1.7 and 1.0, re-
spectively), increase in distance on
the 6-minute walk test (48 vs 52 m),
death or hospital readmission for car-
diac cause (59% vs 58%), death
from any cause (28% vs 28%), hospi-
talization for cardiac cause (42% vs
41%), and operative mortality as-
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to-treat (5% vs 5%). These results
are practically identical as if coming
from a single patient population
divided in half..because they are.
They were selected by ethical sur-
geons aware of the extensive current
literature by many expert surgeon-
scientists working on hibernating
myocardium (no aneurysm, poor ven-
tricles) and overgrown ventricles
resulting from infarction (aneurysm
causing poor function). Perhaps
during the conception of STICH such
knowledge was not available, but per-
haps the performance of SVR (or not)
has reached the level of the ‘‘random-
ized controlled study of the para-
chute.’’ The real message of the
STICH trial is this: if one is pondering
treatment of patients with poor
ventricular function and mild aneurys-
mal dilatation, do not perform the
SVR surgery, because if you do not
send the patient to heaven, you will
only prolong his or her and your own
suffering (increased crossclamp, oper-
ative, and intensive care unit times and
total length of stay) with no clinical
benefit in ensuing years. The STICH
investigators and surgeons are to be
congratulated for their ethical dealing
with this controversial topic. How-
ever, the message that CABG surgery
alone is enough for patients with cor-
onary artery disease and left ven-
tricular aneurysms should not be
interpreted from the STICH trial, as
many patients with disabling left ven-
tricular aneurysms would be at risk for
the wrong treatment.
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